Exploratory biomarker analysis of first-line cobimetinib (C) + paclitaxel (P) in patients (pts) with advanced triple-negative breast cancer (TNBC) from the phase 2 COLET study. (December 2016) - Wongchenko, M.; Miles, D.; Kim, S.B.; Xu, N.; Amler, L.; Yan, Y.; Simmons, B.; McNally, V.; Brufsky, A.